106 related articles for article (PubMed ID: 38295994)
21. Enhanced chemoimmunotherapy of breast cancer in mice by apolipoprotein A1-modified doxorubicin liposomes combined with interleukin-21.
An D; He P; Liu H; Wang R; Yu X; Chen N; Guo X; Li X; Feng M
J Drug Target; 2023 Dec; 31(10):1098-1110. PubMed ID: 37909691
[No Abstract] [Full Text] [Related]
22. A
Kjaergaard J; Hatfield S; Jones G; Ohta A; Sitkovsky M
J Immunol; 2018 Jul; 201(2):782-791. PubMed ID: 29802128
[TBL] [Abstract][Full Text] [Related]
23. Therapy With Carboplatin and Anti-PD-1 Antibodies Before Surgery Demonstrates Sustainable Anti-Tumor Effects for Secondary Cancers in Mice With Triple-Negative Breast Cancer.
Gao M; Wang T; Ji L; Bai S; Tian L; Song H
Front Immunol; 2020; 11():366. PubMed ID: 32194569
[TBL] [Abstract][Full Text] [Related]
24. Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model.
Camilio KA; Wang MY; Mauseth B; Waagene S; Kvalheim G; Rekdal Ø; Sveinbjørnsson B; Mælandsmo GM
Breast Cancer Res; 2019 Jan; 21(1):9. PubMed ID: 30670061
[TBL] [Abstract][Full Text] [Related]
25. Camptothesome Potentiates PD-L1 Immune Checkpoint Blockade for Improved Metastatic Triple-Negative Breast Cancer Immunochemotherapy.
Wang Z; Cordova LE; Chalasani P; Lu J
Mol Pharm; 2022 Dec; 19(12):4665-4674. PubMed ID: 36413426
[TBL] [Abstract][Full Text] [Related]
26. Calcium Phosphate-Reinforced Metal-Organic Frameworks Regulate Adenosine-Mediated Immunosuppression.
Liang L; Yang LL; Wang W; Ji C; Zhang L; Jia Y; Chen Y; Wang X; Tan J; Sun ZJ; Yuan Q; Tan W
Adv Mater; 2021 Nov; 33(45):e2102271. PubMed ID: 34554618
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of histone lysine-specific demethylase 1 elicits breast tumor immunity and enhances antitumor efficacy of immune checkpoint blockade.
Qin Y; Vasilatos SN; Chen L; Wu H; Cao Z; Fu Y; Huang M; Vlad AM; Lu B; Oesterreich S; Davidson NE; Huang Y
Oncogene; 2019 Jan; 38(3):390-405. PubMed ID: 30111819
[TBL] [Abstract][Full Text] [Related]
28. Synthetic high-density lipoproteins delivering liver X receptor agonist prevent atherogenesis by enhancing reverse cholesterol transport.
Yuan W; Yu B; Yu M; Kuai R; Morin EE; Wang H; Hu D; Zhang J; Moon JJ; Chen YE; Guo Y; Schwendeman A
J Control Release; 2021 Jan; 329():361-371. PubMed ID: 33188828
[TBL] [Abstract][Full Text] [Related]
29. Effect of size and pegylation of liposomes and peptide-based synthetic lipoproteins on tumor targeting.
Tang J; Kuai R; Yuan W; Drake L; Moon JJ; Schwendeman A
Nanomedicine; 2017 Aug; 13(6):1869-1878. PubMed ID: 28434931
[TBL] [Abstract][Full Text] [Related]
30. Peptide-Drug Conjugate Targeting Keratin 1 Inhibits Triple-Negative Breast Cancer in Mice.
Ziaei E; Paiva IM; Yao SJ; Sarrami N; Mehinrad P; Lai J; Lavasanifar A; Kaur K
Mol Pharm; 2023 Jul; 20(7):3570-3577. PubMed ID: 37307328
[TBL] [Abstract][Full Text] [Related]
31. Nanodroplet-enhanced sonodynamic therapy potentiates immune checkpoint blockade for systemic suppression of triple-negative breast cancer.
Wu W; Xu M; Qiao B; Huang T; Guo H; Zhang N; Zhou L; Li M; Tan Y; Zhang M; Xie X; Shuai X; Zhang C
Acta Biomater; 2023 Mar; 158():547-559. PubMed ID: 36539109
[TBL] [Abstract][Full Text] [Related]
32. TRAIL-modified, doxorubicin-embedded periodic mesoporous organosilica nanoparticles for targeted drug delivery and efficient antitumor immunotherapy.
Feng X; Li F; Zhang L; Liu W; Wang X; Zhu R; Qiao ZA; Yu B; Yu X
Acta Biomater; 2022 Apr; 143():392-405. PubMed ID: 35259519
[TBL] [Abstract][Full Text] [Related]
33. Enhancing TNBC Chemo-immunotherapy via combination reprogramming tumor immune microenvironment with Immunogenic Cell Death.
Wu S; Liu D; Li W; Song B; Chen C; Chen D; Hu H
Int J Pharm; 2021 Apr; 598():120333. PubMed ID: 33540008
[TBL] [Abstract][Full Text] [Related]
34. Effect of Synthetic High Density Lipoproteins Modification with Polyethylene Glycol on Pharmacokinetics and Pharmacodynamics.
Li D; Fawaz MV; Morin EE; Ming R; Sviridov D; Tang J; Ackermann R; Olsen K; Remaley AT; Schwendeman A
Mol Pharm; 2018 Jan; 15(1):83-96. PubMed ID: 29141139
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Mechanism of a Biomimetic Nanosystem Carrying Doxorubicin and an IDO Inhibitor for Treatment of Advanced Triple-Negative Breast Cancer.
Hu C; Liu Y; Cao W; Li N; Gao S; Wang Z; Gu F
Int J Nanomedicine; 2024; 19():507-526. PubMed ID: 38260240
[TBL] [Abstract][Full Text] [Related]
36. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides.
Gomaraschi M; Calabresi L; Rossoni G; Iametti S; Franceschini G; Stonik JA; Remaley AT
J Pharmacol Exp Ther; 2008 Feb; 324(2):776-83. PubMed ID: 18042829
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of glycolysis-driven immunosuppression with a nano-assembly enhances response to immune checkpoint blockade therapy in triple negative breast cancer.
Ren X; Cheng Z; He J; Yao X; Liu Y; Cai K; Li M; Hu Y; Luo Z
Nat Commun; 2023 Nov; 14(1):7021. PubMed ID: 37919262
[TBL] [Abstract][Full Text] [Related]
38. [Treatment of paclitaxel and doxorubicin changes the immune microenvironment of breast cancer and inhibits the growth of tumor cells in mice].
Wang R; Lang L; Chen S; Wan X; Hou Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2023 Oct; 39(10):891-897. PubMed ID: 37882712
[TBL] [Abstract][Full Text] [Related]
39. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin-isoniazid conjugate regulates immune response and tumor microenvironment to enhance cancer therapy.
Jin C; Li J; Yang X; Zhou S; Li C; Yu J; Wang Z; Wang D; He Z; Jiang Y; Wang Y
Int J Pharm; 2023 Jan; 631():122509. PubMed ID: 36549403
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
